Compare Goldman Sachs Physical Gold ETF (AAAU) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs TransMedics Group Inc — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.4, while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Goldman Sachs Physical Gold ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| AAAU | TMDX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $53.21 | $150.42 |
52-Week Low | $32.74 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused asset, trades at $43.52, up 0.58% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights gold's strength amid cooling US inflation and geopolitical tensions, with spot gold hitting $4,438/oz. The stock lacks disclosed financial ratios, indicating potential data gaps for fundamental analysis.
The outlook for AAAU is tied to gold's momentum, supported by Fed policy expectations and safe-haven demand, but risks include volatility from economic data and overbought conditions. Investors should weigh gold's bullish trends against the absence of company-specific fundamentals and high RSI levels suggesting near-term caution.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
